Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy – An Update
Anticancer Research · 2023
DOI: 10.21873/anticanres.16460 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Anticancer Research, 2023. Verfasst von Ewald Wöll und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, St. Vinzenz Hospital Zams, Zams, Austria; ewald.woell@krankenhaus-zams.at. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Esophageal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
Over the last decade, therapeutic options for patients with gastric cancer have improved significantly. However, despite these recent advances, mortality is still substantial. Surgery and chemotherapy represent the cornerstones of patient management. Immune checkpoint inhibitors as well as targeted treatments such as HER2-directed therapies and antiangiogenic agents contribute to improved patient prognosis. Herein, we present the updated version of an Austrian consensus on the systemic treatment of patients with gastric adenocarcinoma and adenocarcinoma of the lower gastroesophageal junction, including those with human epidermal growth receptor 2 (HER2) overexpression, microsatellite instability, programmed death-ligand 1 (PD-L1)-positive disease, and claudin 18.2 positivity. The consensus considers the curative setting as well as first-line and later-line systemic treatment options in advanced disease. For HER2-positive disease, HER2 testing is discussed in addition to a review of first-line and later-line therapies. Potential future therapies are also listed, with a focus on targeted [e.g., fibroblast growth factor receptor 2 (FGRF2)-directed] treatments that might provide a further step forward in the management of patients with gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, St. Vinzenz Hospital Zams, Zams, Austria; ewald.woell@krankenhaus-zams.at.
- Department of Internal Medicine V, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Internal Medicine and Oncology, Klagenfurt Hospital, Klagenfurt am Wörthersee, Austria.
- Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
- Department of Internal Medicine, Hematology and Oncology, Landesklinikum Wr. Neustadt, Wiener Neustadt, Austria.
- Gastrointestincal Cancer Center, Ordensklinikum Linz, Linz, Austria.
Zitieren
APA
Wöll, E., Amann, A., Eisterer, W., Gerger, A., Grünberger, B., Rumpold, H., Weiss, L., Winder, T., Greil, R., & Prager, G. W. (2023). Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy – An Update. Anticancer Research. https://doi.org/10.21873/anticanres.16460
Vancouver
Wöll E, Amann A, Eisterer W, Gerger A, Grünberger B, Rumpold H, et al. Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy – An Update. Anticancer Research. 2023. doi:10.21873/anticanres.16460
BibTeX
@article{Wll2023,
author = {Wöll, Ewald and Amann, Arno and Eisterer, Wolfgang and Gerger, Armin and Grünberger, Birgit and Rumpold, Holger and Weiss, Lukas and Winder, Thomas and Greil, Richard and Prager, Gerald W},
title = {Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy – An Update},
journal = {Anticancer Research},
year = {2023},
doi = {10.21873/anticanres.16460}
}
EUVIMED